SAN
FRANCISCO, Aug. 20, 2024 /PRNewswire/ -- A
groundbreaking study led by a team of renowned fertility
specialists and data scientists has demonstrated the potential of
artificial intelligence (AI) in optimizing the ovarian stimulation
process for in vitro fertilization (IVF) treatment. The study,
titled "Optimizing Oocyte Yield Utilizing a Machine Learning Model
for Dose and Trigger Decisions: A Multi-Center, Prospective Study,"
was led by Dr. Chelsea Canon, a
reproductive endocrinologist and infertility specialist for RMA of
New York and was published in
Scientific Reports. The study was a multi-center, prospective
analysis of AI's impact on IVF outcomes.
The Alife software, known as Stim Assist™, provides physicians
with personalized, data-driven recommendations based on
patient-specific characteristics and follicle growth. This study is
the first to prospectively investigate the clinical outcomes of IVF
patients when clinicians utilized AI software to assist in
determining the optimal starting dose of follicle-stimulating
hormone (FSH) and the timing of trigger injection.
"The results of our study are incredibly promising," said Dr.
Eric Flisser, one of the lead
authors of the study. "We found a trend towards improved egg yield
and a reduction in FSH usage when physicians used Alife's Stim
Assist™. This suggests that AI has the potential to refine the
starting dose of FSH and narrow down the timing of the trigger
injection during ovarian stimulation, ultimately benefiting
patients by optimizing the number of mature oocytes retrieved and
reducing medication costs."
"The use of AI in IVF represents a significant advancement in
reproductive medicine," said Dr. Alan B Copperman, CEO of RMA of
New York and a collaborator of the
study, "By leveraging AI to optimize ovarian stimulation decisions,
we can potentially improve IVF outcomes and streamline the
treatment process for patients."
The study, which involved 291 patients undergoing IVF treatment
at two clinics in the United
States, underscores the potential of AI to revolutionize the
field of assisted reproductive technology. Dr. Canon and Dr.
Copperman study is the first to evaluate the efficacy of AI for
optimizing ovarian stimulation using prospective post-market data.
The researchers emphasize the need for further studies to validate
these findings and explore the broader application of AI in IVF
treatment.
ABOUT ALIFE HEALTH
Alife is modernizing and
personalizing the IVF process with cutting edge artificial
intelligence technology that aims to improve outcomes and care for
all. The company has built a consortium of partnerships with the
top clinics and most renowned physicians to bring significant
clinical improvements to patients globally. Alife has been
recognized as one of Fast Company's Most Innovative Companies of
2024 and won the 2024 A'Design Award for Information Technologies
Design. Founded by Paxton Maeder-York in 2020, the company is based
in San Francisco and backed by top
tier venture capital investors including Lux Capital, Maveron, and
Union Square Ventures. To learn more visit www.alifehealth.com.
PRESS CONTACT
Carla
English, press@alifehealth.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/alife-health-study-shows-potential-of-ai-model-improving-ovarian-stimulation-decisions-in-ivf-treatment-302225639.html
SOURCE Alife Health